title: Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in anovulatory infertile women.
abstract: Pulsatile administration of human menopausal gonadotropin (hMG) via the subcutaneous route was evaluated in 15 patients with various ovulatory disorders. Administration of hMG was started at a dose of 4.6875 IU (75 IU/day) or 9.375 IU (150 IU/day) per pulse every 90 minutes. Ovulation was observed in 26 (92.9%) of 28 treatment cycles, and two singleton pregnancies were confirmed. Ovarian hyperstimulation was observed in 1 to 26 ovulatory cycles; however, no other side effects were observed during treatment. A regimen of 75 IU/day resulted in a significant increase (P less than 0.0001) of the total dose and prolongation of the treatment period for induction of ovulation, as compared with that of 150 IU/day. Shortened luteal phases occurred in ovulatory cycles induced by pulsatile subcutaneous treatment. Human chorionic gonadotropin administration given every other day until the midluteal phase significantly prolonged the duration of the luteal phase (P less than 0.05). This treatment in patients with the polycystic ovary syndrome was followed by a normalization of luteinizing hormone/follicle-stimulating hormone ratio and resulted in a successful induction of ovulation in 8 to 10 cycles. The present data demonstrated that pulsatile subcutaneous administration of hMG was effective in inducing follicular maturation and ovulation in patients with various types of anovulatory infertility.
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000209:etiology; D000858:Anovulation / Q000097:blood / Q000209:etiology / Q000628:therapy; D004334:Drug Administration Schedule; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D007987:Gonadotropin-Releasing Hormone; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy*; D007279:Injections, Subcutaneous; D008183:Luteal Phase / Q000187:drug effects; D008596:Menotropins / Q000008:administration & dosage*; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications
chemical_list: D012739:Gonadal Steroid Hormones; D006065:Gonadotropins, Pituitary; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins